DK3419622T3 - Behandling af neurodegenerativ øjensygdom med pridopidin - Google Patents

Behandling af neurodegenerativ øjensygdom med pridopidin Download PDF

Info

Publication number
DK3419622T3
DK3419622T3 DK17757261.7T DK17757261T DK3419622T3 DK 3419622 T3 DK3419622 T3 DK 3419622T3 DK 17757261 T DK17757261 T DK 17757261T DK 3419622 T3 DK3419622 T3 DK 3419622T3
Authority
DK
Denmark
Prior art keywords
pridopidine
treatment
eye disease
neurodegenerative eye
neurodegenerative
Prior art date
Application number
DK17757261.7T
Other languages
Danish (da)
English (en)
Inventor
Hermann Kurt Russ
Michal Geva
Ralph Laufer
Aric Orbach
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Application granted granted Critical
Publication of DK3419622T3 publication Critical patent/DK3419622T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17757261.7T 2016-02-24 2017-02-24 Behandling af neurodegenerativ øjensygdom med pridopidin DK3419622T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662299290P 2016-02-24 2016-02-24
PCT/US2017/019266 WO2017147366A1 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Publications (1)

Publication Number Publication Date
DK3419622T3 true DK3419622T3 (da) 2024-06-03

Family

ID=59686581

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17757261.7T DK3419622T3 (da) 2016-02-24 2017-02-24 Behandling af neurodegenerativ øjensygdom med pridopidin

Country Status (10)

Country Link
US (1) US11738012B2 (enExample)
EP (1) EP3419622B1 (enExample)
JP (1) JP7034488B2 (enExample)
AU (1) AU2017223838B2 (enExample)
CA (1) CA3015512C (enExample)
DK (1) DK3419622T3 (enExample)
ES (1) ES2979123T3 (enExample)
HU (1) HUE066769T2 (enExample)
PL (1) PL3419622T3 (enExample)
WO (1) WO2017147366A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US20220062255A1 (en) * 2016-02-24 2022-03-03 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
MX383462B (es) 2017-09-08 2025-03-14 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
CA3128250C (en) * 2019-03-15 2024-01-16 Michael Hayden Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
JP2024536181A (ja) * 2021-10-11 2024-10-04 プリレニア ニューロセラピューティクス リミテッド 神経変性眼疾患を治療するためのプリドピジン及びその類似体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
BRPI0810161A2 (pt) 2007-04-12 2014-12-30 Nsab Af Neurosearch Sweden Ab Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
CA2688439A1 (en) 2007-05-31 2008-12-11 Joseph Weinstock Treatment of age-related macular degeneration
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
EA027748B1 (ru) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения
CA2884260A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
HUE058288T2 (hu) 2014-01-22 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin módosított hatóanyag-leadású készítményei
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
KR20200031446A (ko) 2018-09-14 2020-03-24 삼성전자주식회사 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치

Also Published As

Publication number Publication date
PL3419622T3 (pl) 2024-07-08
ES2979123T3 (es) 2024-09-24
EP3419622A1 (en) 2019-01-02
CA3015512A1 (en) 2017-08-31
EP3419622A4 (en) 2019-07-10
CA3015512C (en) 2024-01-16
US20190046516A1 (en) 2019-02-14
HUE066769T2 (hu) 2024-09-28
EP3419622B1 (en) 2024-03-06
US11738012B2 (en) 2023-08-29
JP7034488B2 (ja) 2022-03-14
AU2017223838A1 (en) 2018-09-06
AU2017223838B2 (en) 2022-09-29
WO2017147366A1 (en) 2017-08-31
JP2019507758A (ja) 2019-03-22

Similar Documents

Publication Publication Date Title
DK3419622T3 (da) Behandling af neurodegenerativ øjensygdom med pridopidin
DK3448999T3 (da) Oligonukleotider til behandling af øjensygdom
DK3516060T3 (da) Antisense-oligonukleotider til behandling af øjensygdom
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
IL247738B (en) Handling glare in eye tracking
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3506904T3 (da) Behandling af demens
DK3548061T3 (da) Behandling af neurologiske sygdomme
DK3458052T3 (da) Kombinationsbehandling af cancer
IL262852A (en) Treatment of complement-mediated disorders
EP3378442A4 (en) IMPROVED ACCOMMODATIVE INTRAOCULAR LENS
DK3973959T3 (da) Behandling af kolestatisk kløe med seladelpar
EP3397995A4 (en) LENS
DK3393579T3 (da) Øjenbehandlingssystem
HUE053443T2 (hu) Heteroaril vegyületek szembetegségek kezelésére
DK3307267T3 (da) Behandling af multipel sklerose
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
EP3335678A4 (en) ADJUSTABLE INTRAOCULAR LENS
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3848028T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3151814T3 (da) Behandling af en hudlæsion